Medicago clinical trials
Acquired by Tanabe Pharma Corporation, Sep 18, 2013 · source ↗
The registry lists 18 studies whose lead sponsor is Medicago. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 7, 2023.
Before and after it joined Tanabe Pharma Corporation
- First submitted before Medicago became part of Tanabe Pharma Corporation
- 3
- First submitted after Medicago became part of Tanabe Pharma Corporation
- 14
- Unclear, or no submission date
- 1
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Medicago18 studies
Something wrong with this grouping? Tell us on the Tanabe Pharma Corporation page.
Studies
Recruiting first, then most recently updated. Showing 18 of 18. All Tanabe Pharma Corporation studies →
- Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）TerminatedNCT05065619Phase 1/2
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in AdultsCompletedNCT03301051Phase 3
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy AdultsCompletedNCT03321968Phase 3
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and OlderCompletedNCT04622592Phase 1/2
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the ElderlyCompletedNCT03739112Phase 3
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 VaccineWithdrawnNCT05040789Phase 3
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.CompletedNCT04450004Phase 1
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in AdultsActive, not recruitingNCT04636697Phase 2/3
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in AdultsCompletedNCT01991587Phase 1/2
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.CompletedNCT01991561Phase 2
Sponsor listed in the registry: Medicago · First submitted the day Medicago became part of Tanabe Pharma Corporation
- Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy AdultsCompletedNCT02768805Phase 2
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in AdultsCompletedNCT02233816Phase 2
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly PopulationCompletedNCT02236052Phase 2
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly AdultsCompletedNCT02831751Phase 2
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.CompletedNCT02022163Phase 1
Sponsor listed in the registry: Medicago · First submitted after Medicago became part of Tanabe Pharma Corporation
- Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in AdultsCompletedNCT01302990Phase 1
Sponsor listed in the registry: Medicago · First submitted before Medicago became part of Tanabe Pharma Corporation
- Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza VaccineCompletedNCT01244867Phase 2
Sponsor listed in the registry: Medicago · First submitted before Medicago became part of Tanabe Pharma Corporation
- Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy AdultsCompletedNCT00984945Phase 1
Sponsor listed in the registry: Medicago · First submitted before Medicago became part of Tanabe Pharma Corporation